Prior authorization requires patients or their providers to secure pre-approval as a condition of payment or insurance coverage of services. In a recent ASCO survey, 75% of oncology practices cited prior authorization as a significant practice pressure. In a 2021 survey led by the American Medical Association (AMA), practices reported an average of 41 prior authorization requests per week, accounting for approximately 13 hours of practice time—or nearly two business days. Learn more.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
On June 8, CancerLinQ® LLC and HealthVerity, Inc. announced a collaboration that will create the nation’s premier real-world oncology data ecosystem to advance cancer care and research for government and public health agencies.
The American Society of Clinical Oncology (ASCO) has made new resources available through its refreshed Survivorship Compendium—an online library of practice tools designed and curated to help oncologists develop high-quality, equitable cancer survivorship care programs and improve existing programs for patients who have completed their initial cancer treatment or who have transitioned to maintenance or preventive therapies.
The Centers for Medicare & Medicaid Services Office of Minority Health’s Minority Research Grant Program recently released a notice of funding opportunity for three grants totaling up to $1 million for researchers at minority-serving institutions. Eligible institutions include Historically Black Colleges and Universities, Hispanic-Serving Institutions, Asian American and Native American Pacific Islander-Serving Institutions, and Tribal colleges and Universities.
In a collaboration announced June 4, ASCO will work with the World Health Organization (WHO) to measure and improve the quality of cancer care internationally. The goal is to achieve health-related targets of the U.N. Sustainable Development Goals and WHO Global Action Plan on Non-Communicable Diseases and help cancer professionals provide the best possible care to their patients.
On May 27, 2022, the Food and Drug Administration approved the following for the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC):
On May 27, 2022, the Food and Drug Administration granted accelerated approval to tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
On May 25, 2022, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in combination with azacitidine for newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Today, JCO Oncology Practice published a new ASCO study which found that among respondents participating in the survey, most oncology practices do not systematically collect data related to sexual orientation and gender identity (SOGI).
On May 20, 2022, the Food and Drug Administration approved azacitidine (Vidaza, Celgene Corp.) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) today jointly released recommendations that address the lack of equity, diversity, and inclusion (EDI) in cancer clinical trials. Published in the Journal of Clinical Oncology, “Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement” details specific actions to engage the entire cancer clinical trial ecosystem in expanding the participation of underrepresented individuals in research that advances progress against cancer.
Last week, American Society of Clinical Oncology (ASCO) CEO Clifford A. Hudis, MD, FACP, FASCO, participated in Health Equity: Advocacy and Access, an online panel hosted by The Cancer Letter which focused on role of policy in ensuring equitable access to care.
Today, JCO Oncology Practice, a journal of the American Society of Clinical Oncology (ASCO), published a special series that examines the causes of disparities in cancer care and outcomes in the U.S. Hispanic/Latinx population and offers potential solutions to increase equity among this group. "Disparities in Cancer Care and Scientific Knowledge in Hispanic/Latinx People in the United States” features 18 articles and editorials that present new data and opportunities on a wide variety of topics, including prevention and screening, genetic testing, clinical trial enrollment and participation, access to affordable health care, and workforce representation, among others.
A new report found that 13% of prior authorization denials in the Medicare Advantage (MA) program were for service requests that met Medicare fee-for-service coverage rules, likely delaying or preventing patient care. The report, conducted by the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG), on the impact of prior authorization within MA found that imaging services, stays in post-acute facilities, and injections were three prominent service types among the denials that met Medicare coverage rules.
Proposals to reauthorize the Food and Drug Administration (FDA) user fee agreements include several ASCO priorities, including those that would increase diversity of clinical trials and strengthen the accelerated approval process.